Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma.

MLA

Chen, Ning-Chun, et al. “Beta2-Microglobulin Is a Valuable Marker and Identifies a Poor-Prognosis Subgroup among Intermediate-Risk Patients with Diffuse Large B Cell Lymphoma.” Clinical & Experimental Medicine, vol. 23, no. 7, Nov. 2023, pp. 3759–66. EBSCOhost, https://doi.org/10.1007/s10238-023-01061-w.

APA

Chen, N.-C., Chang, H., Kao, H.-W., Ou, C.-W., Kuo, M.-C., Wang, P.-N., Lin, T.-L., Wu, J.-H., Hung, Y.-S., Su, Y.-J., Ong, Y.-C., & Shih, H.-J. (2023). Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma. Clinical & Experimental Medicine, 23(7), 3759–3766. https://doi.org/10.1007/s10238-023-01061-w

Chicago

Chen, Ning-Chun, Hung Chang, Hsiao-Wen Kao, Che-Wei Ou, Ming-Chung Kuo, Po-Nan Wang, Tung-Liang Lin, et al. 2023. “Beta2-Microglobulin Is a Valuable Marker and Identifies a Poor-Prognosis Subgroup among Intermediate-Risk Patients with Diffuse Large B Cell Lymphoma.” Clinical & Experimental Medicine 23 (7): 3759–66. doi:10.1007/s10238-023-01061-w.